ST
STTK.US Shattuck Labs Inc
- Market cap
- USD 466M
- P/E
- -
- P/B
- 2.45x
- ROE
- -38.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is STTK.US undervalued?
Graham numberThe Graham number of Shattuck Labs Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shattuck Labs Inc fundamental analysis
No fundamental analysis for Shattuck Labs Inc yet.
Shattuck Labs Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shattuck Labs Inc
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxici…
Full company profileShattuck Labs Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shattuck Labs Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 22.4M | 9.89M | 9.93M | 30.0M | 652K | 1.66M | 5.72M | 1.00M | 0.00 |
| Gross Profit | -2.37M | -19.3M | 9.93M | 28.6M | 652K | -2.39M | 827K | -1.95M | - |
| Operating Income | -6.15M | -25.1M | -36.9M | -45.3M | -103M | -92.0M | -80.6M | -51.5M | -78.3M |
| EBITDA | -4.50M | -24.5M | -36.3M | -43.6M | -100M | -83.3M | -71.6M | -45.1M | -70.1M |
| Net Income | -7.39M | -24.0M | -35.4M | -45.0M | -101M | -87.3M | -75.4M | -48.8M | -73.5M |
| EPS | -0.49 | -0.57 | -0.85 | -1.07 | -2.37 | -2.05 | -1.49 | -0.70 | -0.40 |
| Balance Sheet | |||||||||
| Total Assets | 68.2M | 45.0M | 349M | 299M | 205M | 160M | 91.0M | 91.0M | 208M |
| Total Liabilities | 79.2M | 79.5M | 39.1M | 26.8M | 29.2M | 14.9M | 11.4M | 8.64M | 14.3M |
| Shareholders' Equity | -11.1M | -34.5M | 310M | 272M | 176M | 145M | 79.6M | 82.4M | 194M |
| Cash & Short-term Investments | 60.4M | 39.1M | 335M | 269M | 161M | 131M | 73.0M | 78.1M | 196M |
| Total Debt | - | - | - | - | 4.90M | 4.20M | 3.41M | 2.42M | 2.45M |
| Cash Flow | |||||||||
| Operating Cash Flow | -6.90M | -21.0M | -33.7M | -57.1M | -94.5M | -81.2M | -60.5M | -39.9M | -54.8M |
| Capital Expenditure | 1.18M | 470K | 727K | 7.93M | 11.6M | 407K | 59.0K | 71.0K | 339K |
| Free Cash Flow | -8.08M | -21.4M | -34.4M | -65.0M | -106M | -81.6M | -60.6M | -40.0M | -55.0M |
| Ratios | |||||||||
| ROE | - | - | -11.4% | -16.5% | -57.1% | -60.3% | -94.7% | -59.2% | -38.0% |
| ROA | -10.8% | -53.3% | -10.2% | -15.1% | -49.0% | -54.7% | -82.8% | -53.6% | -35.3% |
| Net Profit Margin | -32.9% | -242.6% | -356.7% | -149.8% | -15,423.5% | -5,268.4% | -1,318.1% | -4,880.9% | - |
| Debt to Equity | - | - | - | - | 0.03x | 0.03x | 0.04x | 0.03x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shattuck Labs Inc dividends
Shattuck Labs Inc has not paid dividends in the last 8 fiscal years.
Who owns Shattuck Labs Inc
- Insiders 4.02%
- Institutions 89.58%
- Public & others 6.40%
- Shares outstanding 102M
- Free float 67.5M
Top funds holding STTK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock | 3.49M | 3.42% | +12.12% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 3.46M | 3.40% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.37M | 2.32% | 0.00% | Sep 2026 |
| T. Rowe Price Health Sciences | 2.35M | 2.31% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.05M | 2.01% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.97M | 1.93% | +2.69% | Oct 2026 |
| T. Rowe Price Instl Small-Cap Stock | 1.88M | 1.84% | +11.76% | Sep 2026 |
| abrdn Life Sciences Investors | 845K | 0.83% | +11.99% | Oct 2026 |
| Fidelity Small Cap Index | 672K | 0.66% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 668K | 0.66% | -0.38% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 511K | 0.50% | +0.27% | Oct 2026 |
| Vanguard Russell 2000 ETF | 476K | 0.47% | +35.08% | Sep 2026 |
| Fidelity Select Biotechnology | 392K | 0.38% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 376K | 0.37% | +15.74% | Sep 2026 |
| DWS ESG Biotech LC | 296K | 0.29% | 0.00% | Sep 2026 |
| Vanguard US Momentum Factor ETF | 282K | 0.28% | 0.00% | Sep 2026 |
| Vanguard Explorer Inv | 255K | 0.25% | -20.13% | Sep 2026 |
| iShares Micro-Cap ETF | 248K | 0.24% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 219K | 0.22% | +0.11% | Sep 2026 |
| Northwestern Mutual Ser Small Cap Value | 204K | 0.20% | 0.00% | Sep 2026 |
Top institutions holding STTK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management,Inc. | 13.4M | 13.19% | +36.16% | Jun 2026 |
| Adage Capital Partners Gp LLC | 8.12M | 7.98% | +74.86% | Jun 2026 |
| Redmile Group, LLC | 6.89M | 6.77% | +24.41% | Jun 2026 |
| Orbimed Advisors LLC | 6.31M | 6.19% | 0.00% | Jun 2026 |
| Prosight Management, LP | 5.96M | 5.85% | +19.05% | Jun 2026 |
| BlackRock Inc | 3.94M | 3.87% | +670.51% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 3.75M | 3.68% | 0.00% | Jun 2026 |
| NEXTBio Capital Management LP | 3.73M | 3.66% | +18.33% | Jun 2026 |
| Deep Track Capital, LP | 3.71M | 3.64% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.21M | 3.15% | +40.87% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.64M | 2.59% | +48.14% | Jun 2026 |
| Pinnacle Associates Inc | 1.87M | 1.84% | +36.78% | Jun 2026 |
| Wellington Management Company LLP | 1.77M | 1.74% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.58M | 1.56% | +145.43% | Jun 2026 |
| Clark Estates Inc | 1.42M | 1.39% | -0.96% | Sep 2026 |
| Point72 Asset Management, L.P. | 1.17M | 1.15% | +13.55% | Jun 2026 |
| State Street Corp | 1.03M | 1.01% | +289.13% | Jun 2026 |
| Boxer Capital Management, LLC | 1.00M | 0.98% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 947K | 0.93% | 0.00% | Jun 2026 |
| Aberdeen Group PLC | 755K | 0.74% | -46.32% | Sep 2026 |
Shattuck Labs Inc company profile
- Company name
- Shattuck Labs Inc
- Ticker
- STTK.US
- Exchange
- USA Stocks
- Listed since
- Oct 9, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 40
- Fiscal year end
- December
- Address
- 500 West 5th Street, Austin, TX, United States, 78701
- Phone
- 512 900 4690
- Website
- shattucklabs.com
About Shattuck Labs Inc
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs Inc management
10- Dr. Taylor H. Schreiber M.D., Ph.D.Co-Founder, CEO & Director · born 1980
- Mr. Andrew R. Neill M.B.A.Chief Financial Officer · born 1986
- Dr. Arunthathy Nirmalini Pandite M.B.A., M.D.Chief Medical Officer · born 1959
- Mr. Brad HuckabeeVice President of Accounting & SEC reporting
- Dr. Abhinav A. Shukla Ph.D.Chief Technical Officer · born 1973
- Mr. Suresh de Silva Ph.D.Chief Scientific Officer
- Dr. Stephen Stout J.D., Ph.D.General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer · born 1975
- Ms. Casi DeYoungChief Business Officer · born 1971
- Dr. Thomas Lampkin Pharm.D.Senior Vice President of Regulatory Affairs
- Ms. Kelli Collin M.B.A., M.S.Senior Vice President of Quality